hwk-007
·Code: HWK-007
hwk-007: developed by 1 company · 1 clinical trial tracked.
hwk-007 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect hwk-007 to WHWK; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could hwk-007 → WHWK affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Whitehawk Therapeutics, Inc. (WHWK) | Phase 1 |
Clinical Trials (1)
A Phase 1 First-in-Human Study of PTK7-Directed Antibody Drug Conjugate HWK-007 in Participants With Advanced Solid Tumors
Primary endpoint: Determine Maximum Tolerated Dose (MTD)
Interventionalopen226 targetStarted 2025-12Completion 2028-1212 sites · United StatesWhitehawk Therapeutics, Inc.
Frequently asked questions
Who is developing hwk-007?
hwk-007 is being developed by Whitehawk Therapeutics, Inc..
How many clinical trials involve hwk-007?
BioSniper tracks 1 clinical trial involving hwk-007.